These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19207033)

  • 1. ABCB1 polymorphisms and the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under antiretroviral therapy.
    Estrela Rde C; Ribeiro FS; Barroso PF; Tuyama M; Gregório SP; Dias-Neto E; Struchiner CJ; Suarez-Kurtz G
    Pharmacogenomics; 2009 Feb; 10(2):311-8. PubMed ID: 19207033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects.
    Estrela RC; Santoro AB; Barroso PF; Tuyama M; Suarez-Kurtz G
    Clin Pharmacol Ther; 2008 Aug; 84(2):205-7. PubMed ID: 18288082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men.
    Kohlrausch FB; de Cássia Estrela R; Barroso PF; Suarez-Kurtz G
    Br J Clin Pharmacol; 2010 Jan; 69(1):95-8. PubMed ID: 20078617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil.
    Vergara TR; Estrela RC; Suarez-Kurtz G; Schechter M; Cerbino-Neto J; Barroso PF
    Ther Drug Monit; 2006 Apr; 28(2):175-9. PubMed ID: 16628127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid and plasma HIV-1 RNA levels and lopinavir concentrations following lopinavir/ritonavir regimen.
    Yilmaz A; Ståhle L; Hagberg L; Svennerholm B; Fuchs D; Gisslén M
    Scand J Infect Dis; 2004; 36(11-12):823-8. PubMed ID: 15764168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
    Ghosn J; Chaix ML; Peytavin G; Bresson JL; Galimand J; Girard PM; Raffi F; Cohen-Codar I; Delfraissy JF; Rouzioux C
    J Antimicrob Chemother; 2008 Jun; 61(6):1344-7. PubMed ID: 18343806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lopinavir/ritonavir combined with twice-daily 400 mg indinavir: pharmacokinetics and pharmacodynamics in blood, CSF and semen.
    Isaac A; Taylor S; Cane P; Smit E; Gibbons SE; White DJ; Drake SM; Khoo S; Back DJ
    J Antimicrob Chemother; 2004 Aug; 54(2):498-502. PubMed ID: 15254024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
    Rosso R; Di Biagio A; Dentone C; Gattinara GC; Martino AM; Viganò A; Merlo M; Giaquinto C; Rampon O; Bassetti M; Gatti G; Viscoli C
    J Antimicrob Chemother; 2006 Jun; 57(6):1168-71. PubMed ID: 16606636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of MDR1 C1236T polymorphism on lopinavir plasma concentration and virological response in HIV-1-infected children.
    Bellusci CP; Rocco C; Aulicino P; Mecikovsky D; Curras V; Hegoburu S; Bramuglia GF; Bologna R; Sen L; Mangano A
    Gene; 2013 Jun; 522(1):96-101. PubMed ID: 23528223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No influence of the P-glycoprotein genotype (MDR1 C3435T) on plasma levels of lopinavir and efavirenz during antiretroviral treatment.
    Winzer R; Langmann P; Zilly M; Tollmann F; Schubert J; Klinker H; Weissbrich B
    Eur J Med Res; 2003 Dec; 8(12):531-4. PubMed ID: 14711599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
    Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K
    J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients.
    Wyen C; Fuhr U; Frank D; Aarnoutse RE; Klaassen T; Lazar A; Seeringer A; Doroshyenko O; Kirchheiner JC; Abdulrazik F; Schmeisser N; Lehmann C; Hein W; Schömig E; Burger DM; Fätkenheuer G; Jetter A
    Clin Pharmacol Ther; 2008 Jul; 84(1):75-82. PubMed ID: 18183034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients.
    Seminari E; Gentilini G; Galli L; Hasson H; Danise A; Carini E; Dorigatti F; Soldarini A; Lazzarin A; Castagna A
    J Antimicrob Chemother; 2005 Oct; 56(4):790-2. PubMed ID: 16143711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations.
    Gutiérrez F; Padilla S; Masiá M; Navarro A; Gallego J; Hernández I; Ramos JM; Martin-Hidalgo A
    Antivir Ther; 2004 Feb; 9(1):105-13. PubMed ID: 15040542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine.
    Manavi K; McDonald A; Al-Sharqui A
    AIDS; 2007 Mar; 21(5):643-5. PubMed ID: 17314527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of lopinavir/ritonavir in pregnancy.
    Lambert JS; Else LJ; Jackson V; Breiden J; Gibbons S; Dickinson L; Back DJ; Brennan M; Connor EO; Boyle N; Fleming C; Coulter-Smith S; Khoo SH
    HIV Med; 2011 Mar; 12(3):166-73. PubMed ID: 20726906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The lopinavir/ritonavir-associated rise in lipids is not related to lopinavir or ritonavir plasma concentration.
    Bierman WF; van Vonderen MG; Veldkamp AI; Burger DM; Danner SA; Reiss P; van Agtmael MA
    Antivir Ther; 2011; 16(5):647-55. PubMed ID: 21817186
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.
    Ma Q; Brazeau D; Zingman BS; Reichman RC; Fischl MA; Gripshover BM; Venuto CS; Slish JC; DiFrancesco R; Forrest A; Morse GD
    Pharmacogenomics; 2007 Mar; 8(3):227-35. PubMed ID: 17324111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.